Ziftomenib

N/A

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameZiftomenib
Drug Alias NameKOMZIFTIKO-381KO-382KO-539MI-463 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMenin/Histone-lysine N-methyltransferase 2A MLL inhibitors
TargetsMeninHistone-lysine N-methyltransferase 2A
Therapy Area/IndicationsHematologic NeoplasmsGastrointestinal Stromal TumorsSarcoma, Myeloid +[10] 
Global Approved IndicationsLeukemia, Myeloid, Acute
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/11/13
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Michigan
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterKura Oncology Inc
Inactive CompaniesKyowa Kirin Co LtdMassachusetts General Hospital
Active IndicationsHematologic NeoplasmsGastrointestinal Stromal TumorsSarcoma, Myeloid +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A